



Please type a plus sign (+) inside this box → ☒

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)



Application Number	09/785,019
Filing Date	February 15, 2001
First Named Inventor	Alexander Gaiger
Group Art Unit	
Examiner Name	
Attorney Docket No.	210121.465C4

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____ _____ _____
--	---	--

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	James M. Verna, Ph.D.	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	June 14, 2001	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	Monica Steinborn	
Signature		Date: June 14, 2001



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231.

June 14, 2001
Date

Monica Steinborn
Monica Steinborn

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alexander Gaiger et al.
Application No. : 09/785,019
Filed : February 15, 2001
For : COMPOSITIONS AND METHODS FOR WT1
SPECIFIC IMMUNOTHERAPY
Docket No. : 210121.465C4

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 09/685,830, filed October 9, 2000; which is a continuation-in-part of USAN 09/684,361, filed October 6, 2000; which is a continuation-in-part of USAN 09/276,484, filed March 25, 1999; which is a continuation-in-part of USAN 09/164,223, filed September 30, 1998. The references listed on pages 1-13 of the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office

in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



James M. Verna, Ph.D.
Registration No. 33,287

JEP:mls

Enclosures:

Postcard
Form PTO/SB/21
Form PTO-1449

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.465C4APPLICATION NO.
09/785,019

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Alexander Gaiger et al.

FILING DATE

February 15, 2001

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,350,840	09/27/94	Call et al.	536	23.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION IF APPROPRIATE	
					YES	NO
	AB	WO99/58135	11/18/99	PCT		
	AC	WO95/29995	11/09/95	PCT		
	AD	WO95/06725	03/09/95	PCT		
	AE	WO 91/07509	05/30/91	PCT		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AF	Aaronson and Todaro, "Development of 3t3-like lines from Balb/c mouse embryo cultures: transformation susceptibility to SV40," <i>J. Cell. Physiol.</i> 72(2):141-148, October 1968.
	AG	Adachi et al., "Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1)," <i>Oncogene</i> 13: 2197-2203, 1996.
	AH	Algar et al., "A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines," <i>Oncogene</i> 12: 1005-1014, 1996.
	AI	Armstrong et al., "The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo," <i>Mechanisms of Development</i> 40: 85-97, 1992.
	AJ	Bellantuono et al., "Selective elimination of leukemic progenitors by allorestricted CTL specific for WILMS Tumor Antigen-1 (WT-1)," <i>Blood</i> , 94(10):532A-533A, November 15, 1999.
	AK	Bergmann et al., "High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome," <i>Blood</i> 90(3): 1217-1225, 1997.
	AL	Bergmann et al., "Wilms Tumor Gene Expression in Acute Myeloid Leukemias," <i>Leukemia and Lymphoma</i> 25: 435-443, 1997.
	AM	Brenner et al., "RNA polymerase chain reaction detects different levels of four alternatively spliced WT1 transcripts in Wilms' tumors," <i>Oncogene</i> 7: 1431-1433, 1992.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.465C4APPLICATION NO.
09/785,019**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Alexander Gaiger et al.

FILING DATE

February 15, 2001

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	BB				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BC	Brieger et al., "The Expression of the Wilms' Tumor Gene in Acute Myelocytic Leukemias as Possible Marker for Leukemic Blast Cells," <i>Leukemia</i> 8(12): 2138-2143, 1994.
	BD	Brieger et al., "The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR," <i>Annals of Oncology</i> 6: 811-816, 1995.
	BE	Buckler et al., "Isolation, Characterization, and Expression of the Murine Wilms' Tumor Gene (WT1) During Kidney Development," <i>Molecular and Cellular Biology</i> 11: 1707-1712, 1991.
	BF	Call et al., "Isolation and Characterization of a Zinc Finger Polypeptide Gene at the Human Chromosome 11 Wilms' Tumor Locus," <i>Cell</i> 60: 509-520, 1990.
	BG	Carapeti et al., "Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia," <i>Eur. J. Haematol.</i> 58: 346-349, 1997.
	BH	Charles et al., "Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study," <i>J. Clin. Pathol.: Mol. Pathol.</i> 50: 138-144, 1997.
	BI	Charles et al., "Immunohistochemical detection of the Wilms' tumour gene WT1 in desmoplastic small round cell tumour," <i>Histopathology</i> 30: 312-314, 1997.
	BJ	Chen et al., "T-cells for tumor therapy can be obtained from antigen-loaded sponge implants," <i>Cancer Research</i> 54(4):1065-1070, February 15, 1994.
	BK	Chesebro et al., "Characterization of Ia8 antigen, THY-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines," <i>The Journal of Immunology</i> 117(4):1267-1274, October 1976.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.465C4APPLICATION NO.
09/785,019**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANTS

Alexander Gaiger et al.

FILING DATE

February 15, 2001

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CC	De Bruijn et al., "Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses," <i>Eur J Immunol</i> 21(12):2963-2970, December 1991.
	CD	Deavin et al., "Statistical comparison of established T-cell epitope predictors against a large database of human and murine antigens," <i>Molecular Immunology</i> , 33(2):145-155, 1996.
	CE	Drummond et al., "Repression of the Insulin-Like Growth Factor Gene by the Wilms Tumor Suppressor WT1," <i>Science</i> 257: 674-677, 1992.
	CF	Feller and de la Cruz, "Tsites (Version 1.1) A computer program to determine T cell epitopes using four predictive algorithms," <i>Nature</i> 349: 720-721, 1991.
	CG	Foster et al., "Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model," <i>Cancer Research</i> 57(16):3325-3330, August 15, 1997.
	CH	Frazier et al., "Expression of the Tumor Suppressor Gene WT1 in Both Human and Mouse Bone Marrow," <i>Blood</i> 86: 4704-4706, 1995 (letter).
	CI	Gaiger et al., "WT1: A new leukemia and cancer antigen A," <i>Proceedings of the Annual Meeting of the American Association for Cancer Research</i> , 40:424, 1999.
	CJ	Gaiger et al., "Immunity to WT1 in animal models and leukemia patients," <i>Blood</i> , 94(10):78, November 15, 1999.
	CK	Gaiger et al., "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," <i>Blood</i> 96(4):1480-1489, August 15, 2000.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.465C4APPLICATION NO.
09/785,019**INFORMATION DISCLOSURE STATEMENT***(Use several sheets if necessary)*APPLICANTS
Alexander Gaiger et al.FILING DATE
February 15, 2001

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	DB					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	DC	Gillis and Smith, "Long term culture of tumour-specific cytotoxic T cells," <i>Nature</i> 268:154-156, July 14, 1977.
	DD	Glynn et al., "Cross-resistance to the transplantation of syngeneic friend, moloney, and rauscher virus-induced tumors," <i>Cancer Research</i> 28(3):434-439, March 1968.
	DE	Goodyer et al., "Repression of the retinoic acid receptor- α gene by the Wilms' tumor suppressor gene product, wt1," <i>Oncogene</i> 10: 1125-1129, 1995.
	DF	Haber et al., "A dominant mutation in the Wilms tumor gene <i>WT1</i> cooperates with the viral oncogene <i>E1A</i> in transformation of primary kidney cells," <i>Proc. Natl. Acad. Sci. USA</i> 89: 6010-6014, 1992.
	DG	Haber et al., "Alternative splicing and genomic structure of the Wilms tumor gene <i>WT1</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 88: 9618-9622, 1991.
	DH	Haber et al., "An Internal Deletion within an 11p13 Zinc Finger Gene Contributes to the Development of Wilms' Tumor," <i>Cell</i> 61: 1257-1269, 1990.
	DI	Hamilton et al., "High affinity binding sites for the Wilms' tumour suppressor protein WT1," <i>Nucleic Acids Research</i> 23(2): 277-284, 1995.
	DJ	Harrington et al., "Inhibition of Colony-stimulating Factor-1 Promoter Activity by the Product of the Wilms' Tumor Locus," <i>The Journal Of Biological Chemistry</i> 268(28): 21271-21275, 1993.
	DK	Harrington et al., "Inhibition of Colony-stimulating Factor-1 Promoter Activity by the Product of the Wilms' Tumor Locus," <i>The Journal Of Biological Chemistry</i> 268(28): 21271-21275, 1993.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.465C4APPLICATION NO.
09/785,019**INFORMATION DISCLOSURE STATEMENT***(Use several sheets if necessary)*

APPLICANTS

Alexander Gaiger et al.

FILING DATE

February 15, 2001

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION IF APPROPRIATE	
					YES	NO
	EB					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	EC	Horibata and Harris, "Mouse myelomas and lymphomas in culture," <i>Experimental Cell Research</i> 60:61-77, 1970.
	ED	Huang et al., "Tissue, Developmental, and Tumor-Specific Expression of Divergent Transcripts in Wilms Tumor," <i>Science</i> 250: 991-994, 1990.
	EE	Inoue et al., "Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human Leukemia," <i>Blood</i> 89(4): 1405-1412, 1997.
	EF	Inoue et al., "Long-Term Follow-Up of Minimal Residual Disease in Leukemia Patients by Monitoring WT1 (Wilms Tumor Gene) Expression Levels," <i>Blood</i> 88: 2267-2278, 1996.
	EG	Inoue et al., "Wilms' Tumor Gene (WT1) Competes With Differentiation-Inducing Signal in Hematopoietic Progenitor Cells," <i>Blood</i> 91(8): 2969-2976, 1998.
	EH	Inoue et al., "WT1 as a New Prognostic Factor and a New Marker for the Detection of Minimal Residual Disease in Acute Leukemia," <i>Blood</i> 84: 3071-3079, 1994.
	EI	King-Underwood and Pritchard-Jones, "Wilms' Tumor (WT1) Gene Mutations Occur Mainly in Acute Myeloid Leukemia and May Confer Drug Resistance," <i>Blood</i> 91(8): 2961-2968, 1998.
	EJ	King-Underwood et al., "Mutations in the Wilms' Tumor Gene WT1 in Leukemias," <i>Blood</i> 91: 2961-2968, 1998.
	EK	Kreidberg et al., "WT-1 Is Required for Early Kidney Development," <i>Cell</i> 74: 679-691, 1993.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C4		APPLICATION NO. 09/785,019	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE February 15, 2001		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	FB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	FC	Kudoh et al., "Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apoptotic cell death in response to retinoic acid," <i>Oncogene 13</i> : 1431-1439, 1996.					
	FD	Kudoh et al., "G ₁ phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes," <i>Proc. Natl. Acad. Sci. USA</i> 92: 4517-4521, 1995.					
	FE	Kwok and Higuchi, "Avoiding false positives with PCR," <i>Nature</i> 339:237-238, May 18, 1989.					
	FF	Larsson et al., "Subnuclear Localization of WT1 in Splicing or Transcription Factor Domains Is Regulated by Alternative Splicing," <i>Cell</i> 81: 391-401, 1995.					
	FG	Ljunggren et al., "Empty MHC class I molecules come out in the cold," <i>Nature</i> 346:476-480, August 2, 1990.					
	FH	Lozzio and Lozzio, "Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome," <i>Blood</i> 45(3):321-334, March 1975.					
	FI	Luo et al., "The tumor suppressor gene WT1 inhibits <i>ras</i> -mediated transformation," <i>Oncogene 11</i> : 743-750, 1995.					
	FJ	Madden et al., "Transcriptional Repression Mediated by the WT1 Wilms Tumor Gene Product," <i>Science</i> 253: 1550-1552, 1991.					
	FK	Maurer et al., "The Wilms' tumor gene is expressed in a subset of CD34 progenitors and downregulated early in the course of differentiation in vitro," <i>Experimental Hematology</i> 25: 945-950, 1997.					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C4		APPLICATION NO. 09/785,019	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE February 15, 2001		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	GB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	GC	Menke et al., "Wilms' Tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells," <i>Oncogene</i> 12: 537-546, 1996.					
	GD	Menssen et al., "Detection By Monoclonal Antibodies Of The Wilms' Tumor (WT1) Nuclear Protein In Patients With Acute Leukemia," <i>Int. J. Cancer</i> 70: 518-523, 1997.					
	GE	Menssen et al., "Presence of Wilms' tumor gene (<i>wt1</i>) transcripts and the WT1 nuclear protein in the majority of human acute leukemias," <i>Leukemia</i> 9: 1060-1067, 1995.					
	GF	Menssen et al., "Wilms' Tumor Gene Expression in Human CD34 Hematopoietic Progenitors During Fetal Development and Early Clonogenic Growth," <i>Blood</i> 89(9): 3486-3487, 1997 (letter).					
	GG	Miwa et al., "Expression of the Wilms' Tumor Gene (WT1) in Human Leukemias," <i>Leukemia</i> 6(5): 405-409, 1992.					
	GH	Miyagi et al., "Expression of the Candidate Wilms' Tumor Gene, <i>WT1</i> , in Human Leukemia Cells," <i>Leukemia</i> 7(7): 970-977, 1993.					
	GI	Morris et al., "Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus," <i>Oncogene</i> 6: 2339-2348, 1991.					
	GJ	Mundlos et al., "Nuclear localization of the protein encoded by the Wilms' tumor gene <i>WT1</i> in embryonic and adult tissues," <i>Development</i> 119: 1329-1341, 1993.					
	GK	Murata et al., "The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells," <i>FEBS Letters</i> 409: 41-45, 1997.					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C4		APPLICATION NO. 09/785,019	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE February 15, 2001		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	HB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	HC	Nakagama et al., "Sequence and Structural Requirements for High-Affinity DNA Binding by the WT1 Gene Product," <i>Molecular and Cellular Biology</i> 15(3): 1489-1498, 1995.					
	HD	Nichols et al., "WT1 Induces Expression of Insulin-like Growth Factor 2 in Wilms' Tumor Cells," <i>Cancer Research</i> 55: 4540-4543, 1995.					
	HE	Ogawa et al., "Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay," <i>Bone Marrow Transplantation</i> 21: 525-527, 1998.					
	HF	Old et al., "Antigenic properties of chemically induced tumors," <i>Annals of the New York Academy of Sciences</i> 101:80-107, November 20, 1962.					
	HG	Osaka et al., "WT1 Contributes To Leukemogenesis: Expression Patterns In 7,12-Dimethylbenz[a]Anthracene (DMBA)-Induced Leukemia," <i>International Journal of Cancer</i> 72: 696-699, 1997.					
	HH	Parker et al., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>Journal of Immunology</i> 152: 163-175, 1994.					
	HI	Patek et al., "Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis," <i>Nature</i> 276:510-511, November 30, 1978.					
	HJ	Patmasiriwat et al., "Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities," <i>Leukemia</i> 10: 1127-1133, 1996.					
	HK	Pelletier et al., "Expression of the Wilms' tumor gene WT1 in the murine urogenital system," <i>Genes & Development</i> 5: 1345-1356, 1991.					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C4		APPLICATION NO. 09/785,019	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE February 15, 2001		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	IA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	IB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	IC	Pelletier et al., "Germline Mutations in the Wilms' Tumor Suppressor Gene Are Associated with Abnormal Urogenital Development in Denys-Drash Syndrome," <i>Cell</i> 67: 437-447, 1991.					
	ID	Phelan et al., "Wilms' Tumor Gene, <i>WT1</i> , mRNA Is Down-regulated during Induction of Erythroid and Megakaryocytic Differentiation of K562 Cells," <i>Cell Growth & Differentiation</i> 5: 677-686, 1994.					
	IE	Pogue et al., "Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and <i>in vitro</i> immunogenicity," <i>Proc. Natl. Acad. Sci. USA</i> 92: 8166-8170, 1995.					
	IF	Pritchard-Jones et al., "The candidate Wilms' tumour gene is involved in genitourinary development," <i>Nature</i> 346: 194-197, 1990.					
	IG	Pritchard-Jones et al., "The Wilms tumour (<i>WT1</i>) gene is mutated in a secondary leukaemia in a WAGR patient," <i>Human Molecular Genetics</i> 3(9): 1633-1637, 1994.					
	IH	Rackley et al., "Expression of the Wilms' Tumor Suppressor Gene <i>WT1</i> during Mouse Embryogenesis," <i>Cell Growth & Differentiation</i> 4: 1023-1031, 1993.					
	II	Ramani and Cowell, "The Expression Pattern Of Wilms' Tumour Gene (<i>WT1</i>) Product In Normal Tissues And Paediatric Renal Tumours," <i>Journal Of Pathology</i> 179: 162-168, 1996.					
	IJ	Rauscher et al., "Binding of the Wilms' Tumor Locus Zinc Finger Protein to the EGR-1 Consensus Sequence," <i>Science</i> 250: 1259-1262, 1990.					
	IK	Rauscher, "The <i>WT1</i> Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor," <i>FASEB J.</i> 7: 896-903, 1993.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C4		APPLICATION NO. 09/785,019	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE February 15, 2001		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	JA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	JB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	JC		Rauscher et al., "Characterization of monoclonal antibodies directed to the amino-terminus of the WT1, Wilms' tumor suppressor," <i>Hybridoma</i> , 17(2):191-198, April 1998.				
	JD		Reddy et al., "WT1-mediated Transcriptional Activation Is Inhibited by Dominant Negative Mutant Proteins," <i>The Journal Of Biological Chemistry</i> 270(18): 10878-10884, 1995.				
	JE		Rothbard and Taylor, "A sequence pattern common to T cell epitopes," <i>EMBO Journal</i> , 7(1):93-100, 1988.				
	JF		Rupprecht et al., "The Wilms' Tumor Suppressor Gene WT1 Is Negatively Autoregulated," <i>The Journal Of Biological Chemistry</i> 269(8): 6198-6206, 1994.				
	JG		Sadovnikova et al., "Generation of human tumor-reactive cytotoxic T-cells against peptides presented by non-self HLA class I molecules," <i>Eur.J. Immunol.</i> , 28:193-200, 1998.				
	JH		Schmid et al., "Prognostic significance of WT1 gene expression at diagnosis in adult <i>de novo</i> acute myeloid leukemia," <i>Leukemia</i> 11: 639-643, 1997.				
	JI		Sekiya et al., "Downregulation of Wilms' Tumor Gene (wt1) During Myelomonocytic Differentiation in HL60 Cells," <i>Blood</i> 83(7): 1876-1882, 1994.				
	JJ		Sharma et al., "Molecular Cloning of Rat Wilms' Tumor Complementary DNA and a Study of Messenger RNA Expression in the Urogenital System and the Brain," <i>Cancer Research</i> 52: 6407-6412, 1992.				
	JK		Silberstein et al., "Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer," <i>Proc. Natl. Acad. Sci. USA</i> 94: 8132-8137, 1997.				
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C4		APPLICATION NO. 09/785,019	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE February 15, 2001		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	KA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	KB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	KC	Skeiky et al., "Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of <i>Mycobacterium tuberculosis</i> ," <i>Infection and Immunity</i> 67(8):3998-4007, August 1999.					
	KD	Slavin and Strober, "Spontaneous murine B-cell leukaemia," <i>Nature</i> 272:624-626, April 13, 1978.					
	KE	Svedberg et al., "Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program," <i>Oncogene</i> 15: 1-8, 1997.					
	KF	Tadokoro et al., "Genomic Organization of the Human WT1 Gene," <i>Jpn. J. Cancer Res.</i> 83: 1198-1203, 1992.					
	KG	Tadokoro et al., "Intragenic homozygous deletion of the <i>WT1</i> gene in Wilms' tumor," <i>Oncogene</i> 7: 1215-1221, 1992.					
	KH	Tadokoro et al., "PCR Detection of 9 Polymorphisms in the WT1 Gene," <i>Human Molecular Genetics</i> 2(12): 2205-2206, 1993.					
	KI	Tadokoro et al., "TaqI RFLPs at the Wilms' tumor gene (WT1)," <i>Nucleic Acids Research</i> 19(9): 2514, 1991.					
	KJ	Telerman et al., "Identification of the cellular protein encoded by the human Wilms' tumor (<i>WT1</i>) gene," <i>Oncogene</i> 7: 2545-2548, 1992.					
	KK	Toes et al., "Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts," <i>Int. J. Cancer</i> , 66:686-691, 1996.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.465C4		APPLICATION NO. 09/785,019	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANTS Alexander Gaiger et al.			
				FILING DATE February 15, 2001		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	MA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION IF APPROPRIATE	
						YES	NO
	MB						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	MC	Tsurutani et al., "cDNA cloning and developmental expression of the porcine homologue of WT1," <i>Gene</i> 211(2): 215-220, 1998.					
	MD	Wang et al., "A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1," <i>Proc. Natl. Acad. Sci. USA</i> 90: 8896-8900, 1993.					
	ME	Wang et al., "The Wilms' Tumor Gene Product WT1 Activates or Suppresses Transcription through Separate Functional Domains," <i>The Journal Of Biological Chemistry</i> 268(13): 9172-9175, 1993.					
	MF	Wang et al., "The Wilms' Tumor Gene Product, WT1, Represses Transcription of the Platelet-derived Growth Factor A-chain Gene," <i>The Journal Of Biological Chemistry</i> 267(31): 21999-22002, 1992.					
	MG	Wang et al., "WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein," <i>Oncogene</i> 10(6): 1243-1247, 1995.					
	MH	Watson et al., "Leukemia viruses associated with mouse myeloma cells," <i>Proceeding of the National Academy of Sciences</i> 66(2):344-351, June 1970.					
	MI	Werner et al., "Inhibition of Cellular Proliferation by the Wilms' Tumor Suppressor WT1 Is Associated with Suppression of Insulin-Like Growth Factor I Receptor Gene Expression," <i>Molecular and Cellular Biology</i> 15: 3516-3522, 1995.					
	MJ	Wu et al., "GATA-1 Transactivates the WT1 Hematopoietic Specific Enhancer," <i>The Journal Of Biological Chemistry</i> 270(11): 5944-5949, 1995.					
	MK	Yamagami et al., "Growth Inhibition of Human Leukemic Cells by WT1 (Wilms Tumor Gene) Antisense Oligodeoxynucleotides: Implications for the Involvement of WT1 in Leukemogenesis," <i>Blood</i> 87(7): 2878-2884, 1996.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.465C4APPLICATION NO.
09/785,019**INFORMATION DISCLOSURE STATEMENT***(Use several sheets if necessary)*

APPLICANTS

Alexander Gaiger et al.

FILING DATE

February 15, 2001

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	NA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	NB					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	NC		Ye et al., "Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation," <i>The EMBO Journal</i> 15(20): 5606-5615, 1996.			
	ND					
	NE					
	NF					
	NG					
	NH					
	NI					
	NJ					
	NK					

EXAMINER

DATE CONSIDERED

*** EXAMINER:**

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).